Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category

Adam B. Polis, Nicola Abate, Alberico L. Catapano, Christie M. Ballantyne, Michael H. Davidson, Steven S. Smugar, Andrew M. Tershakovec

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Patients with diabetes mellitus (DM) and metabolic syndrome are at increased risk of coronary heart disease (CHD). Studies have shown differential statin efficacy on low-density lipid cholesterol (LDL-C) by CHD risk strata. Objective: The aim of this study was to evaluate the consistency of effect with ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, or rosuvastatin in patients with DM, metabolic syndrome, or neither condition (No DM/metabolic syndrome), stratified by the National Cholesterol Education Panel Adult Treatment Panel III (NCEP ATP III) CHD risk group. Methods: Post hoc analyses of 2 multicenter, double-blind, randomized, 6-week studies comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg, or rosuvastatin 10, 20, or 40 mg. Treatments were compared by pooling across all doses for LDL-C reduction and NCEP LDL-C goal attainment in patients with DM, metabolic syndrome without DM, or No DM/metabolic syndrome across NCEP CHD risk strata. Results: NCEP LDL-C goal attainment was lowest in the high-risk group with atherosclerotic vascular disease (12-64) and greatest in the moderate and low-risk groups (84-100). In contrast, LDL-C reduction was generally similar irrespective of disease or risk subgroup. All treatments were generally well tolerated, with overall similar safety regardless of disease and risk level. Conclusions: In these studies, CHD risk strata were inversely related to the likelihood of attaining NCEP LDL-C goals, but did not appear to affect the percentage LDL-C change from baseline. This demonstrates the need for especially aggressive cholesterol lowering necessary to reach the lower LDL-C goal for high-risk patients.

Original languageEnglish (US)
Pages (from-to)601-610
Number of pages10
JournalMetabolic Syndrome and Related Disorders
Volume7
Issue number6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Simvastatin
LDL Cholesterol
Cholesterol
Education
Lipids
Diabetes Mellitus
Coronary Disease
S 10
Ezetimibe
Atorvastatin Calcium
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Vascular Diseases
Safety

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category. / Polis, Adam B.; Abate, Nicola; Catapano, Alberico L.; Ballantyne, Christie M.; Davidson, Michael H.; Smugar, Steven S.; Tershakovec, Andrew M.

In: Metabolic Syndrome and Related Disorders, Vol. 7, No. 6, 01.12.2009, p. 601-610.

Research output: Contribution to journalArticle

@article{7f00818bced541afb6be8280e06341c1,
title = "Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category",
abstract = "Background: Patients with diabetes mellitus (DM) and metabolic syndrome are at increased risk of coronary heart disease (CHD). Studies have shown differential statin efficacy on low-density lipid cholesterol (LDL-C) by CHD risk strata. Objective: The aim of this study was to evaluate the consistency of effect with ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, or rosuvastatin in patients with DM, metabolic syndrome, or neither condition (No DM/metabolic syndrome), stratified by the National Cholesterol Education Panel Adult Treatment Panel III (NCEP ATP III) CHD risk group. Methods: Post hoc analyses of 2 multicenter, double-blind, randomized, 6-week studies comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg, or rosuvastatin 10, 20, or 40 mg. Treatments were compared by pooling across all doses for LDL-C reduction and NCEP LDL-C goal attainment in patients with DM, metabolic syndrome without DM, or No DM/metabolic syndrome across NCEP CHD risk strata. Results: NCEP LDL-C goal attainment was lowest in the high-risk group with atherosclerotic vascular disease (12-64) and greatest in the moderate and low-risk groups (84-100). In contrast, LDL-C reduction was generally similar irrespective of disease or risk subgroup. All treatments were generally well tolerated, with overall similar safety regardless of disease and risk level. Conclusions: In these studies, CHD risk strata were inversely related to the likelihood of attaining NCEP LDL-C goals, but did not appear to affect the percentage LDL-C change from baseline. This demonstrates the need for especially aggressive cholesterol lowering necessary to reach the lower LDL-C goal for high-risk patients.",
author = "Polis, {Adam B.} and Nicola Abate and Catapano, {Alberico L.} and Ballantyne, {Christie M.} and Davidson, {Michael H.} and Smugar, {Steven S.} and Tershakovec, {Andrew M.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1089/met.2009.0009",
language = "English (US)",
volume = "7",
pages = "601--610",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category

AU - Polis, Adam B.

AU - Abate, Nicola

AU - Catapano, Alberico L.

AU - Ballantyne, Christie M.

AU - Davidson, Michael H.

AU - Smugar, Steven S.

AU - Tershakovec, Andrew M.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: Patients with diabetes mellitus (DM) and metabolic syndrome are at increased risk of coronary heart disease (CHD). Studies have shown differential statin efficacy on low-density lipid cholesterol (LDL-C) by CHD risk strata. Objective: The aim of this study was to evaluate the consistency of effect with ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, or rosuvastatin in patients with DM, metabolic syndrome, or neither condition (No DM/metabolic syndrome), stratified by the National Cholesterol Education Panel Adult Treatment Panel III (NCEP ATP III) CHD risk group. Methods: Post hoc analyses of 2 multicenter, double-blind, randomized, 6-week studies comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg, or rosuvastatin 10, 20, or 40 mg. Treatments were compared by pooling across all doses for LDL-C reduction and NCEP LDL-C goal attainment in patients with DM, metabolic syndrome without DM, or No DM/metabolic syndrome across NCEP CHD risk strata. Results: NCEP LDL-C goal attainment was lowest in the high-risk group with atherosclerotic vascular disease (12-64) and greatest in the moderate and low-risk groups (84-100). In contrast, LDL-C reduction was generally similar irrespective of disease or risk subgroup. All treatments were generally well tolerated, with overall similar safety regardless of disease and risk level. Conclusions: In these studies, CHD risk strata were inversely related to the likelihood of attaining NCEP LDL-C goals, but did not appear to affect the percentage LDL-C change from baseline. This demonstrates the need for especially aggressive cholesterol lowering necessary to reach the lower LDL-C goal for high-risk patients.

AB - Background: Patients with diabetes mellitus (DM) and metabolic syndrome are at increased risk of coronary heart disease (CHD). Studies have shown differential statin efficacy on low-density lipid cholesterol (LDL-C) by CHD risk strata. Objective: The aim of this study was to evaluate the consistency of effect with ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, or rosuvastatin in patients with DM, metabolic syndrome, or neither condition (No DM/metabolic syndrome), stratified by the National Cholesterol Education Panel Adult Treatment Panel III (NCEP ATP III) CHD risk group. Methods: Post hoc analyses of 2 multicenter, double-blind, randomized, 6-week studies comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg, or rosuvastatin 10, 20, or 40 mg. Treatments were compared by pooling across all doses for LDL-C reduction and NCEP LDL-C goal attainment in patients with DM, metabolic syndrome without DM, or No DM/metabolic syndrome across NCEP CHD risk strata. Results: NCEP LDL-C goal attainment was lowest in the high-risk group with atherosclerotic vascular disease (12-64) and greatest in the moderate and low-risk groups (84-100). In contrast, LDL-C reduction was generally similar irrespective of disease or risk subgroup. All treatments were generally well tolerated, with overall similar safety regardless of disease and risk level. Conclusions: In these studies, CHD risk strata were inversely related to the likelihood of attaining NCEP LDL-C goals, but did not appear to affect the percentage LDL-C change from baseline. This demonstrates the need for especially aggressive cholesterol lowering necessary to reach the lower LDL-C goal for high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=73649091798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649091798&partnerID=8YFLogxK

U2 - 10.1089/met.2009.0009

DO - 10.1089/met.2009.0009

M3 - Article

VL - 7

SP - 601

EP - 610

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 6

ER -